More on StemCells (STEM): Q2 beats on EPS but comes up short on revenue. Total sales were up 6%...

More on StemCells (STEM): Q2 beats on EPS but comes up short on revenue. Total sales were up 6% Y/Y, on a 14% increase in product sales. Operating expenses -24%, R&D expenses -26%, and SG&A expenses -16%, all of which helped to boost bottom line margins.